JLJia Liu

Jia Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jia Liu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuroprotective Effects of Angong Niuhuang Pill in Stroke: A Systematic Review of Preclinical and Clinical Evidence

    by Xue Cao, Xin Wang, Yukun Tian, Xiangran Meng, Yuning Qin, Mengqi Wang, Youzhu Su, Liyun He, Jia Liu

    Background: Stroke is the second leading cause of death and the third leading cause of disability-adjusted life years lost. A narrow therapeutic window and the complex, dynamic nature of stroke pathophysiology limit current neuroprotective therapies. Angong Niuhuang Pill (ANP) is a traditional Chinese medicine emergency prescription used to treat acute conditions and is reported to have neuroprotective effects. The aim of this review was to evaluate the neuroprotection of ANP and to assess its efficacy and safety in the treatment of stroke. Methods: This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We systematically searched four databases and selected studies that met the inclusion criteria (n = 16). The methodological quality was assessed using SYRCLE risk of bias tool (for animal studies), the Cochrane Risk of Bias tool (for Randomised Controlled Trials (RCTs)), and AMSTAR 2 (for systematic reviews/meta-analyses). Data were integrated using a narrative synthesis method. Results: 12 preclinical studies suggested that ANP may provide neuroprotection in stroke via multiple pathways, half of them indicating anti-cell death properties. Two high-quality preclinical studies examine the mechanism of ANP in ischemic stroke (IS), namely via the PI3K/AKT axis and microcirculation. One RCT showed that ANP increased the proportion of patients achieving an mRS score of 0-2 at six months in patients with basal ganglia haemorrhage (26.2% vs. 2.6%) and the other one, which exhibits high methodological quality, showed for patients with moderate-to-severe acute IS, ANP showed no overall benefit in day-14 infarct or oedema volumes, although a significant reduction was observed in the large artery atherosclerosis subgroup (-12.3 mL, P = 0.03). Two meta-analyses indicated that ANP was associated with higher GCS (MD = 2.01, 95% CI [1.04, 2.98], P < 0.00001) and lower NIHSS scores, but both had low methodological quality. There was no statistically significant difference in the incidence of adverse events between the two groups. Discussion: This review found that ANP has a relatively definite neuroprotective effect and can improve the clinical efficacy of stroke patients. However, due to the limited number of included studies and significant differences in study design, study population, and outcome definition, the existing evidence shows considerable heterogeneity, resulting in relatively low study quality and making reliable quantitative meta-analysis difficult. Future research should use relevant quality assessment tools in study design and implementation to enhance the credibility of evidence and thereby promote the generation of high-quality evidence. Conclusion: This review synthesizes evidence of neuroprotective effect and clinical effectiveness, suggesting potential neuroprotective benefit with an overall favorable safety profile.


  • Open Access

    Chinese herbal medicine Ding Kun Dan for menopausal syndrome: A systematic review and meta-analysis of randomized controlled trials

    by Youzhu Su, Jia Liu, Yuxian Wang, Xiao Xiao, Rui Liu, Xinxin Liu, Chen Shen, Rui Su, Xuefei Wang, Jianping Liu


  • Open Access

    Therapeutic potential and possible mechanisms for acupuncture in treating low anterior resection syndrome

    by Meng-Qi Wang, Heng-Chang Liu, Wen-Yun Hou, Jia Liu

  • Open Access

    Analysis of the Registration Information on Interventions of Acupuncture and Moxibustion Trials in the International Clinical Trials Registry Platform

    by Yali Liu, Wenjie Chen, Yingxin Tan, Xingyue Yang, Jia Liu, Tingting Lu, Shiyan Yan, Liyun He, Baoyan Liu

    Purpose. To analyze and compare the clinical registration information about acupuncture and moxibustion for intervention characteristics. Methods. Clinical trials from the International Clinical Trials Registry Platform of the World Health Organization in acupuncture and moxibustion were comprehensively collected from 2013 to 2015; data were independently screened and extracted by two retrievers, and relevant data involving either basic descriptions or intervention characteristics were analyzed. Results. 425 acupuncture and moxibustion registered clinical trials were included; 88.00% (374/425) were designed as controlled studies, among which 38.59% (164/425) had sham acupuncture as the control group. The most common diseases were pain‐related at approximately 19.29% (82/425) of trials. Reports on the intervention information in these acupuncture and moxibustion clinical studies were not sufficiently presented; these reports included the reporting of names of points (39.8%), the method of needle stimulation (32.5%), needle type (29.6%), needle retention time (34.1%), the number of treatment sessions (22.4%), and the frequency and duration of treatment sessions (38.1%). Conclusion. The registration information for the clinical trials of acupuncture and moxibustion was quite low according to this investigational study. Steps should be taken to improve the quality of acupuncture and moxibustion registration information.